HCA
CYTK icon

Heck Capital Advisors’s Cytokinetics CYTK Stock Holding History

Heck Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27
Closed -$1.27K – 374
2024
Q4 		$1.27K Buy
+27
New +$1.4K ﹤0.01% 688

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Heck Capital Advisors's CYTK Position: Q1 2025 in Review

Heck Capital Advisors sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 27 shares — an estimated $1.27K sold.

Heck Capital Advisors first reported a position in CYTK in Q4 2024 and held it in 1 quarter. The position peaked at $1.27K in Q4 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Heck Capital Advisors reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 27 Cytokinetics shares in Q1 2025, an estimated $1.27K.
  • Heck Capital Advisors first reported a position in Cytokinetics in Q4 2024 and held it in 1 quarter.
  • Heck Capital Advisors's Cytokinetics position peaked at $1.27K in Q4 2024.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.